Merck and the associated logos are trademarks of Merck & Co., Inc.

Merck & Co., Inc. (known as MSD outside the United States and Canada) is a global biopharmaceutical leader dedicated to translating breakthrough science into life-changing therapies. With a strong foundation in virology, immunology, and oncology, Merck has built a robust legacy in liver care—most notably through innovative therapies for viral hepatitis—and is now advancing novel solutions for metabolic liver diseases, including metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD).

Merck’s liver portfolio includes Zepatier® (elbasvir/grazoprevir), a pan-genotypic, once-daily oral regimen for chronic hepatitis C virus (HCV) infection that delivers high sustained virologic response (SVR) rates across diverse patient populations. Through its global access initiatives, Merck remains committed to advancing viral hepatitis elimination efforts, especially in low- and middle-income countries where the burden remains high.

Expanding into the growing field of MASH/MASLD, Merck is progressing a multi-pronged pipeline targeting the metabolic, inflammatory, and fibrotic drivers of disease progression. This includes investigational therapies such as GLP-1 receptor agonists, THR-β selective agonists, and anti-fibrotic agents designed to reduce hepatic fat, resolve inflammation, and reverse fibrosis. These candidates aim to address the systemic nature of MASLD and its links to cardiometabolic risk, positioning Merck at the forefront of next-generation liver therapeutics.

Merck is also exploring the application of its leading immuno-oncology agent, Keytruda® (pembrolizumab), in hepatocellular carcinoma (HCC)—a frequent outcome of advanced MASLD/MASH—both as monotherapy and in combination with targeted therapies. This approach reflects Merck’s commitment to delivering holistic liver care across the full disease continuum, from early-stage metabolic dysfunction to liver cancer.

Guided by science, powered by collaboration, and driven by impact, Merck continues to build on its legacy in hepatology with bold innovations designed to transform outcomes for patients living with chronic and progressive liver diseases worldwide.